Alcohol
Volume 37, Issue 1 , Pages 23-33, August 2005

Treatment with and withdrawal from finasteride alter ethanol intake patterns in male C57BL/6J mice: Potential role of endogenous neurosteroids?

  • Matthew M. Ford

      Affiliations

    • Department of Behavioral Neuroscience (L-470), Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239-3098, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-503-220-8262, ext. 57619; fax: +1-503-494-6877.
  • ,
  • Jeffrey D. Nickel

      Affiliations

    • Department of Behavioral Neuroscience (L-470), Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239-3098, USA
  • ,
  • Deborah A. Finn

      Affiliations

    • Department of Behavioral Neuroscience (L-470), Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR 97239-3098, USA
    • Portland Alcohol Research Center and VAMC Research, Portland, OR 97239, USA

Received 20 September 2005; received in revised form 8 November 2005; accepted 8 November 2005.

Abstract 

Exogenous administration of the γ-aminobutyric acid (GABA)-ergic neurosteroid allopregnanolone (ALLO) can increase ethanol intake in rats and mice. To determine the contribution of endogenous neurosteroids (i.e., ALLO and related pregnane steroids) in the regulation of established ethanol consumption patterns in male C57BL/6J (B6) mice, the 5α-reductase (5α-R) enzyme inhibitor, finasteride (FIN), was chronically administered and then subsequently withdrawn. Mice were provided daily 2-h limited access to a 10% vol/vol ethanol solution (10E) and water in lickometer chambers during the dark phase. Following the establishment of stable 10E intake patterns, mice were injected intraperitoneally with either vehicle (20% wt/vol 2-hydroxypropyl-β-cyclodextrin; n=8) or FIN (50mg/kg; n=16) for 7 days. Effects of withdrawal from FIN treatment were subsequently assessed for an additional 7 days. Ethanol intakes were significantly decreased with acute FIN treatment (days 1–3) and during early withdrawal (days 1–3). Acute FIN treatment was also associated with an extended latency to first bout, reduced first bout size, and greatly attenuated sipper contact count during the initial 20-min interval of 10E access. These findings collectively indicated that acute FIN treatment markedly attenuated the initiation of 10E consumption during the limited access sessions. The influence of FIN on 10E intake patterns was largely dissipated with chronic treatment, suggesting that compensatory changes in neurosteroid modulation of inhibitory tone may have occurred. Thus, acute FIN treatment modulated ethanol intake patterns in a manner opposite to that previously demonstrated for a physiologically relevant, exogenous ALLO dose, consistent with the ability of a5α-R inhibitor to block ALLO biosynthesis. Manipulation of endogenous neurosteroid activity via biosynthetic enzyme inhibition or antagonism of steroid binding to the GABA type A receptor may prove to be a beneficial pharmacotherapeutic strategy in the intervention of alcohol abuse and alcoholism.

Keywords: Alcohol, Self-administration, Drinking patterns, Lickometer, Bout microarchitecture, Neurosteroid metabolism

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0741-8329(05)00200-4

doi:10.1016/j.alcohol.2005.11.002

Alcohol
Volume 37, Issue 1 , Pages 23-33, August 2005